Pancreatic cancer is on the rise in the United States, but there's another, less common type called pancreatic neuroendocrine ...
Pancreatic neuroendocrine cancers are rare cancers. They start in the neuroendocrine cells of the pancreas. Your healthcare team might call them pancreatic neuroendocrine neoplasms, or pancreatic NENs ...
Pat Gulhati, MD, PhD, discusses findings from a comprehensive analysis of genetic, immunological, and signaling pathway variations in pancreatic cancer.
A cystic neoplasm needs to be considered when a patient presents with a fluid-containing pancreatic lesion. Cystic neoplasms of the pancreas may be more frequent than previously recognized and are ...
News-Medical.Net on MSN2d
FGFR2 identified as key driver in KRAS-mutated pancreatic cancer progressionPrecancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had ...
In a recent study, precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS ...
Medical Xpress on MSN16d
Mayo Clinic researchers identify a measurable genetic mutation as a significant predictor of metastasis and survival in pancreatic cancerA new study by Mayo Clinic Comprehensive Cancer Center researchers found that the presence of a specific genetic mutation — KRAS circulating tumor DNA (ctDNA) — strongly indicates a higher risk of ...
Bottom line: Colorectal cancer and pancreatic ductal adenocarcinoma that harbored the KRAS G12C mutation often carried other genetic alterations that can be associated with resistance to KRAS G12C ...
MedPage Today on MSN4mon
FDA OKs First Drug Targeting NRG1 Gene Fusion in Pancreatic, Lung CancersThe FDA granted accelerated approval to the bispecific antibody zenocutuzumab (Bizengri) for NRG1 gene fusion-positive pancreatic adenocarcinoma and non-small cell lung cancer (NSCLC) on Wednesday.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback